Pacira BioSciences, Selling General Administrative Over Time
| PCRX Stock | USD 17.55 0.17 0.98% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pacira BioSciences, Performance and Pacira BioSciences, Correlation. Pacira |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira BioSciences,. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira BioSciences, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.24) | Earnings Share (1.98) | Revenue Per Share 15.006 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0417 |
The market value of Pacira BioSciences, is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira BioSciences,'s value that differs from its market value or its book value, called intrinsic value, which is Pacira BioSciences,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira BioSciences,'s market value can be influenced by many factors that don't directly affect Pacira BioSciences,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira BioSciences,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira BioSciences, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira BioSciences,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Selling General Administrative Analysis
Compare Pacira BioSciences, and related stocks such as Phibro Animal Health, Dr Reddys Laboratories, and Collegium Pharmaceutical Selling General Administrative Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAHC | 59.3 M | 114.8 M | 122.2 M | 144 M | 148.7 M | 153.3 M | 150.3 M | 168 M | 181.4 M | 187.7 M | 196.5 M | 206.4 M | 226.4 M | 259.8 M | 139.2 M |
| RDY | 71 M | 633.7 M | 709.7 M | 646 M | 683 M | 690 M | 715 M | 720 M | 707 M | 50.1 B | 54.6 B | 62.1 B | 46.5 B | 77.2 B | 73.3 B |
| COLL | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 2.7 M | 18.9 M | 80.6 M | 92.8 M | 126.8 M | 116.4 M | 108.5 M | 114.8 M | 160.4 M | 151.8 M | 97.6 M |
| PBH | 560 K | 56.7 M | 51.5 M | 48.5 M | 81.3 M | 72.4 M | 89.1 M | 184.9 M | 89.8 M | 89.1 M | 85.5 M | 108.5 M | 107.4 M | 106.2 M | 69.2 M |
| HCM | 35.7 M | 35.7 M | 35.7 M | 21.3 M | 22.6 M | 19.6 M | 21.6 M | 24 M | 30.9 M | 39.2 M | 50 M | 89.3 M | 92.2 M | 79.8 M | 48.2 M |
| IXHL | 1.1 M | 2.3 M | 2 M | 862.3 K | 542.3 K | 513.6 K | 3.1 M | 2.5 M | 1.9 M | 1.2 M | 3.4 M | 281 K | 569 K | 17.2 M | 18 M |
| ANIP | 1.1 M | 7 M | 8.2 M | 16.4 M | 17.9 M | 21.2 M | 27.8 M | 31.6 M | 44.1 M | 55.8 M | 65 M | 84.3 M | 127.8 M | 150.4 M | 157.9 M |
| ITCI | 4 M | 4 M | 4 M | 6 M | 10.3 M | 18.2 M | 24.8 M | 23.7 M | 30.1 M | 64.9 M | 186.4 M | 272.6 M | 358.8 M | 317.7 M | 333.5 M |
| ALKS | 2.7 M | 137.6 M | 125.8 M | 116.6 M | 199.9 M | 311.6 M | 374.1 M | 421.6 M | 526.4 M | 568.3 M | 513.3 M | 522.1 M | 198.6 M | 202.3 M | 162.4 M |
Pacira BioSciences, and related stocks such as Phibro Animal Health, Dr Reddys Laboratories, and Collegium Pharmaceutical Selling General Administrative description
My Equities
My Current Equities and Potential Positions
| Pacira BioSciences, | PCRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 17.55
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.